The Brain Tumor Segmentation in Pediatrics (BraTS-PEDs) Challenge: Focus on Pediatrics (CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs)
0
🤖
Sign in to get full access
Overview
- Pediatric brain tumors are the most common cause of cancer-related death in children.
- The five-year survival rate for high-grade gliomas (a type of brain tumor) in children is less than 20%.
- Diagnosing and treating these rare pediatric brain tumors is challenging, often delayed, and requires collaboration between multiple institutions.
Plain English Explanation
Brain tumors are a serious problem for children. These types of tumors are the leading cause of cancer-related deaths in kids. Sadly, the prognosis for the most aggressive brain tumors, called high-grade gliomas, is very poor - less than 20% of children survive 5 years after diagnosis.
The rarity of these pediatric brain tumors makes them difficult to identify and treat effectively. Doctors often have trouble recognizing the signs and diagnosing these tumors early on. The standard approaches to treatment are based on outdated information, not the latest research. To make progress, researchers from different hospitals and research groups need to work together on new ways to detect and treat these tumors.
This challenge, led by several major brain tumor research organizations, aims to bring together clinicians and AI/imaging experts. The goal is to develop automated techniques to analyze brain scans and identify and segment brain tumors more accurately. Improving these AI tools could help with clinical trials and ultimately provide better care for children with brain cancer.
Technical Explanation
This paper introduces the CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs challenge, a collaborative effort focused on advancing the diagnosis and treatment of pediatric brain tumors. The challenge brings together experts from multiple international consortia dedicated to pediatric neuro-oncology and clinical trials.
The key objective is to spur the development of automated segmentation techniques that can accurately identify and delineate different tumor regions in brain scans of children. This is especially important given the rarity of these pediatric brain tumors, which often leads to delayed diagnoses and treatment approaches based on outdated knowledge.
By combining data and expertise from various sources, including the Children's Brain Tumor Network (CBTN), the challenge aims to accelerate the creation of AI-powered tools that can benefit clinical trials and ultimately improve the care of children with brain tumors.
Critical Analysis
The authors acknowledge the significant challenges posed by pediatric brain tumors, including their rarity, delayed diagnoses, and the need for multi-institutional collaboration to drive progress. This challenge represents an important step in addressing these issues by bringing together clinicians and AI/imaging experts to develop more accurate automated tumor segmentation techniques.
One potential limitation is the reliance on data from various consortia, which may introduce variability in data quality and annotation. Additionally, the performance of the developed AI models will need to be thoroughly validated on diverse patient populations to ensure their robustness and generalizability.
Further research may also be needed to explore how these automated segmentation tools can be seamlessly integrated into clinical workflows to support decision-making and improve patient outcomes. Ongoing collaboration and knowledge-sharing between the medical and technical communities will be crucial for realizing the full potential of this initiative.
Conclusion
The CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs challenge represents a valuable effort to address the pressing issue of pediatric brain tumors. By leveraging data and expertise from multiple international consortia, the challenge aims to accelerate the development of automated tumor segmentation tools that could enhance clinical trials and, ultimately, improve the care and outcomes for children with brain cancer.
This summary was produced with help from an AI and may contain inaccuracies - check out the links to read the original source documents!
Related Papers
🤖
0
The Brain Tumor Segmentation in Pediatrics (BraTS-PEDs) Challenge: Focus on Pediatrics (CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs)
Anahita Fathi Kazerooni, Nastaran Khalili, Xinyang Liu, Deep Gandhi, Zhifan Jiang, Syed Muhammed Anwar, Jake Albrecht, Maruf Adewole, Udunna Anazodo, Hannah Anderson, Ujjwal Baid, Timothy Bergquist, Austin J. Borja, Evan Calabrese, Verena Chung, Gian-Marco Conte, Farouk Dako, James Eddy, Ivan Ezhov, Ariana Familiar, Keyvan Farahani, Andrea Franson, Anurag Gottipati, Shuvanjan Haldar, Juan Eugenio Iglesias, Anastasia Janas, Elaine Johansen, Blaise V Jones, Neda Khalili, Florian Kofler, Dominic LaBella, Hollie Anne Lai, Koen Van Leemput, Hongwei Bran Li, Nazanin Maleki, Aaron S McAllister, Zeke Meier, Bjoern Menze, Ahmed W Moawad, Khanak K Nandolia, Julija Pavaine, Marie Piraud, Tina Poussaint, Sanjay P Prabhu, Zachary Reitman, Jeffrey D Rudie, Mariana Sanchez-Montano, Ibraheem Salman Shaikh, Nakul Sheth, Wenxin Tu, Chunhao Wang, Jeffrey B Ware, Benedikt Wiestler, Anna Zapaishchykova, Miriam Bornhorst, Michelle Deutsch, Maryam Fouladi, Margot Lazow, Leonie Mikael, Trent Hummel, Benjamin Kann, Peter de Blank, Lindsey Hoffman, Mariam Aboian, Ali Nabavizadeh, Roger Packer, Spyridon Bakas, Adam Resnick, Brian Rood, Arastoo Vossough, Marius George Linguraru
Pediatric tumors of the central nervous system are the most common cause of cancer-related death in children. The five-year survival rate for high-grade gliomas in children is less than 20%. Due to their rarity, the diagnosis of these entities is often delayed, their treatment is mainly based on historic treatment concepts, and clinical trials require multi-institutional collaborations. Here we present the CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs challenge, focused on pediatric brain tumors with data acquired across multiple international consortia dedicated to pediatric neuro-oncology and clinical trials. The CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs challenge brings together clinicians and AI/imaging scientists to lead to faster development of automated segmentation techniques that could benefit clinical trials, and ultimately the care of children with brain tumors.
Read more7/15/2024
0
BraTS-PEDs: Results of the Multi-Consortium International Pediatric Brain Tumor Segmentation Challenge 2023
Anahita Fathi Kazerooni, Nastaran Khalili, Xinyang Liu, Debanjan Haldar, Zhifan Jiang, Anna Zapaishchykova, Julija Pavaine, Lubdha M. Shah, Blaise V. Jones, Nakul Sheth, Sanjay P. Prabhu, Aaron S. McAllister, Wenxin Tu, Khanak K. Nandolia, Andres F. Rodriguez, Ibraheem Salman Shaikh, Mariana Sanchez Montano, Hollie Anne Lai, Maruf Adewole, Jake Albrecht, Udunna Anazodo, Hannah Anderson, Syed Muhammed Anwar, Alejandro Aristizabal, Sina Bagheri, Ujjwal Baid, Timothy Bergquist, Austin J. Borja, Evan Calabrese, Verena Chung, Gian-Marco Conte, James Eddy, Ivan Ezhov, Ariana M. Familiar, Keyvan Farahani, Deep Gandhi, Anurag Gottipati, Shuvanjan Haldar, Juan Eugenio Iglesias, Anastasia Janas, Elaine Elaine, Alexandros Karargyris, Hasan Kassem, Neda Khalili, Florian Kofler, Dominic LaBella, Koen Van Leemput, Hongwei B. Li, Nazanin Maleki, Zeke Meier, Bjoern Menze, Ahmed W. Moawad, Sarthak Pati, Marie Piraud, Tina Poussaint, Zachary J. Reitman, Jeffrey D. Rudie, Rachit Saluja, MIcah Sheller, Russell Takeshi Shinohara, Karthik Viswanathan, Chunhao Wang, Benedikt Wiestler, Walter F. Wiggins, Christos Davatzikos, Phillip B. Storm, Miriam Bornhorst, Roger Packer, Trent Hummel, Peter de Blank, Lindsey Hoffman, Mariam Aboian, Ali Nabavizadeh, Jeffrey B. Ware, Benjamin H. Kann, Brian Rood, Adam Resnick, Spyridon Bakas, Arastoo Vossough, Marius George Linguraru
Pediatric central nervous system tumors are the leading cause of cancer-related deaths in children. The five-year survival rate for high-grade glioma in children is less than 20%. The development of new treatments is dependent upon multi-institutional collaborative clinical trials requiring reproducible and accurate centralized response assessment. We present the results of the BraTS-PEDs 2023 challenge, the first Brain Tumor Segmentation (BraTS) challenge focused on pediatric brain tumors. This challenge utilized data acquired from multiple international consortia dedicated to pediatric neuro-oncology and clinical trials. BraTS-PEDs 2023 aimed to evaluate volumetric segmentation algorithms for pediatric brain gliomas from magnetic resonance imaging using standardized quantitative performance evaluation metrics employed across the BraTS 2023 challenges. The top-performing AI approaches for pediatric tumor analysis included ensembles of nnU-Net and Swin UNETR, Auto3DSeg, or nnU-Net with a self-supervised framework. The BraTSPEDs 2023 challenge fostered collaboration between clinicians (neuro-oncologists, neuroradiologists) and AI/imaging scientists, promoting faster data sharing and the development of automated volumetric analysis techniques. These advancements could significantly benefit clinical trials and improve the care of children with brain tumors.
Read more7/18/2024
0
The 2024 Brain Tumor Segmentation (BraTS) Challenge: Glioma Segmentation on Post-treatment MRI
Maria Correia de Verdier, Rachit Saluja, Louis Gagnon, Dominic LaBella, Ujjwall Baid, Nourel Hoda Tahon, Martha Foltyn-Dumitru, Jikai Zhang, Maram Alafif, Saif Baig, Ken Chang, Gennaro D'Anna, Lisa Deptula, Diviya Gupta, Muhammad Ammar Haider, Ali Hussain, Michael Iv, Marinos Kontzialis, Paul Manning, Farzan Moodi, Teresa Nunes, Aaron Simon, Nico Sollmann, David Vu, Maruf Adewole, Jake Albrecht, Udunna Anazodo, Rongrong Chai, Verena Chung, Shahriar Faghani, Keyvan Farahani, Anahita Fathi Kazerooni, Eugenio Iglesias, Florian Kofler, Hongwei Li, Marius George Linguraru, Bjoern Menze, Ahmed W. Moawad, Yury Velichko, Benedikt Wiestler, Talissa Altes, Patil Basavasagar, Martin Bendszus, Gianluca Brugnara, Jaeyoung Cho, Yaseen Dhemesh, Brandon K. K. Fields, Filip Garrett, Jaime Gass, Lubomir Hadjiiski, Jona Hattangadi-Gluth, Christopher Hess, Jessica L. Houk, Edvin Isufi, Lester J. Layfield, George Mastorakos, John Mongan, Pierre Nedelec, Uyen Nguyen, Sebastian Oliva, Matthew W. Pease, Aditya Rastogi, Jason Sinclair, Robert X. Smith, Leo P. Sugrue, Jonathan Thacker, Igor Vidic, Javier Villanueva-Meyer, Nathan S. White, Mariam Aboian, Gian Marco Conte, Anders Dale, Mert R. Sabuncu, Tyler M. Seibert, Brent Weinberg, Aly Abayazeed, Raymond Huang, Sevcan Turk, Andreas M. Rauschecker, Nikdokht Farid, Philipp Vollmuth, Ayman Nada, Spyridon Bakas, Evan Calabrese, Jeffrey D. Rudie
Gliomas are the most common malignant primary brain tumors in adults and one of the deadliest types of cancer. There are many challenges in treatment and monitoring due to the genetic diversity and high intrinsic heterogeneity in appearance, shape, histology, and treatment response. Treatments include surgery, radiation, and systemic therapies, with magnetic resonance imaging (MRI) playing a key role in treatment planning and post-treatment longitudinal assessment. The 2024 Brain Tumor Segmentation (BraTS) challenge on post-treatment glioma MRI will provide a community standard and benchmark for state-of-the-art automated segmentation models based on the largest expert-annotated post-treatment glioma MRI dataset. Challenge competitors will develop automated segmentation models to predict four distinct tumor sub-regions consisting of enhancing tissue (ET), surrounding non-enhancing T2/fluid-attenuated inversion recovery (FLAIR) hyperintensity (SNFH), non-enhancing tumor core (NETC), and resection cavity (RC). Models will be evaluated on separate validation and test datasets using standardized performance metrics utilized across the BraTS 2024 cluster of challenges, including lesion-wise Dice Similarity Coefficient and Hausdorff Distance. Models developed during this challenge will advance the field of automated MRI segmentation and contribute to their integration into clinical practice, ultimately enhancing patient care.
Read more5/29/2024
0
Analysis of the BraTS 2023 Intracranial Meningioma Segmentation Challenge
Dominic LaBella, Ujjwal Baid, Omaditya Khanna, Shan McBurney-Lin, Ryan McLean, Pierre Nedelec, Arif Rashid, Nourel Hoda Tahon, Talissa Altes, Radhika Bhalerao, Yaseen Dhemesh, Devon Godfrey, Fathi Hilal, Scott Floyd, Anastasia Janas, Anahita Fathi Kazerooni, John Kirkpatrick, Collin Kent, Florian Kofler, Kevin Leu, Nazanin Maleki, Bjoern Menze, Maxence Pajot, Zachary J. Reitman, Jeffrey D. Rudie, Rachit Saluja, Yury Velichko, Chunhao Wang, Pranav Warman, Maruf Adewole, Jake Albrecht, Udunna Anazodo, Syed Muhammad Anwar, Timothy Bergquist, Sully Francis Chen, Verena Chung, Gian-Marco Conte, Farouk Dako, James Eddy, Ivan Ezhov, Nastaran Khalili, Juan Eugenio Iglesias, Zhifan Jiang, Elaine Johanson, Koen Van Leemput, Hongwei Bran Li, Marius George Linguraru, Xinyang Liu, Aria Mahtabfar, Zeke Meier, Ahmed W. Moawad, John Mongan, Marie Piraud, Russell Takeshi Shinohara, Walter F. Wiggins, Aly H. Abayazeed, Rachel Akinola, Andr'as Jakab, Michel Bilello, Maria Correia de Verdier, Priscila Crivellaro, Christos Davatzikos, Keyvan Farahani, John Freymann, Christopher Hess, Raymond Huang, Philipp Lohmann, Mana Moassefi, Matthew W. Pease, Phillipp Vollmuth, Nico Sollmann, David Diffley, Khanak K. Nandolia, Daniel I. Warren, Ali Hussain, Pascal Fehringer, Yulia Bronstein, Lisa Deptula, Evan G. Stein, Mahsa Taherzadeh, Eduardo Portela de Oliveira, Aoife Haughey, Marinos Kontzialis, Luca Saba, Benjamin Turner, Melanie M. T. Bru{ss}eler, Shehbaz Ansari, Athanasios Gkampenis, David Maximilian Weiss, Aya Mansour, Islam H. Shawali, Nikolay Yordanov, Joel M. Stein, Roula Hourani, Mohammed Yahya Moshebah, Ahmed Magdy Abouelatta, Tanvir Rizvi, Klara Willms, Dann C. Martin, Abdullah Okar, Gennaro D'Anna, Ahmed Taha, Yasaman Sharifi, Shahriar Faghani, Dominic Kite, Marco Pinho, Muhammad Ammar Haider, Alejandro Aristizabal, Alexandros Karargyris, Hasan Kassem, Sarthak Pati, Micah Sheller, Michelle Alonso-Basanta, Javier Villanueva-Meyer, Andreas M. Rauschecker, Ayman Nada, Mariam Aboian, Adam E. Flanders, Benedikt Wiestler, Spyridon Bakas, Evan Calabrese
We describe the design and results from the BraTS 2023 Intracranial Meningioma Segmentation Challenge. The BraTS Meningioma Challenge differed from prior BraTS Glioma challenges in that it focused on meningiomas, which are typically benign extra-axial tumors with diverse radiologic and anatomical presentation and a propensity for multiplicity. Nine participating teams each developed deep-learning automated segmentation models using image data from the largest multi-institutional systematically expert annotated multilabel multi-sequence meningioma MRI dataset to date, which included 1000 training set cases, 141 validation set cases, and 283 hidden test set cases. Each case included T2, T2/FLAIR, T1, and T1Gd brain MRI sequences with associated tumor compartment labels delineating enhancing tumor, non-enhancing tumor, and surrounding non-enhancing T2/FLAIR hyperintensity. Participant automated segmentation models were evaluated and ranked based on a scoring system evaluating lesion-wise metrics including dice similarity coefficient (DSC) and 95% Hausdorff Distance. The top ranked team had a lesion-wise median dice similarity coefficient (DSC) of 0.976, 0.976, and 0.964 for enhancing tumor, tumor core, and whole tumor, respectively and a corresponding average DSC of 0.899, 0.904, and 0.871, respectively. These results serve as state-of-the-art benchmarks for future pre-operative meningioma automated segmentation algorithms. Additionally, we found that 1286 of 1424 cases (90.3%) had at least 1 compartment voxel abutting the edge of the skull-stripped image edge, which requires further investigation into optimal pre-processing face anonymization steps.
Read more5/17/2024